Balancing intellectual monopoly privileges and the need for essential medicines
1 Science and Research Department, World Cancer Research Fund, 19 Harley Street, London, W1G 9QJ, UK
2 London School of Economics, LSE Health, Cowdray House, Houghton Street London, WC2A 2AE, UK
3 College of Law, Medical School, Globalization and Health Project – Centre for Governance of Knowledge and Development, Australian National University, Australia
Globalization and Health 2007, 3:4 doi:10.1186/1744-8603-3-4Published: 12 June 2007
This issue of Globalization and Health presents a paper by Kerry and Lee that considers the TRIPS agreement and the recent policy debate regarding the protection of public health interest, particularly as they pertain to the Doha Declaration. In this editorial, we consider the debate, the conclusions thereof, and identify five questions that should be considered by key stakeholders in ongoing discussions.